Global Adoptive Cell Therapy Industry to 2030 – Featuring Novartis, Gilead Sciences and Cellectis, among others

DUBLIN, April 25, 2022–(BUSINESS WIRE)–The “Adoptive Cellular Therapy Market Report, By Type, By Application, By End-User, And By Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2030” has been added to from ResearchAndMarkets.com offer.

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T-lymphocytes, T-cell receptor (TCR) T-lymphocytes, tumor-infiltrating lymphocytes (TIL), and natural killer (NK) cells.

Adoptive cell therapy involves the use of immune cells that are grown in large numbers in the laboratory, followed by their administration to the body to fight cancer. Sometimes immune cells that naturally recognize melanoma are used, while other times they are modified to recognize and kill melanoma cells. Adoptive cell therapy is also called T cell transfer therapy and cell immunotherapy.

Key players operating in the global adoptive cell therapy market are focused on adopting growth strategies such as product launch, collaboration, and fundraising that are expected to drive the market growth over the period of forecast.

Main characteristics of the study:

  • This report provides an in-depth analysis of the global Adoptive Cell Therapy market and provides market size (Million US$) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), by considering 2021 as the base year.

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.

  • It profiles leading players of the global Adoptive Cell Therapy Market based on the following parameters: Company Highlights, Product Portfolio, Key Highlights, Financial Performance, Strategies

  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics.

  • The Global Adoptive Cell Therapy Market report is targeted at various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

  • Stakeholders would have an ease in making decisions through various strategic matrices used to analyze the global Adoptive Cell Therapy market

Market segmentation :

Global Adoptive Cell Therapy Market, By Type:

Global Adoptive Cell Therapy Market, By Application:

Global Adoptive Cell Therapy Market, By End User:

  • Hospitals

  • Cancer treatment centers

Global Adoptive Cell Therapy Market, By Region:

  • North America

  • WE

  • Canada

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Russia

  • The rest of Europe

  • Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • ASEAN

  • Rest of Asia-Pacific

  • Middle East

  • GCC

  • Israel

  • Rest of the Middle East

  • Africa

  • South Africa

  • central Africa

  • North Africa

Company Profiles

  • Novartis AG.

  • Gilead Sciences, Inc.

  • Castle Creek Biosciences, Inc.

  • Lineage Cell Therapeutics, Inc.

  • Transgene SA

  • Cellectis

  • ImmunityBio, Inc.

  • Sorrento Therapy

  • bluebird bio, inc.

  • Arcellx

  • Sana Biotechnology, Inc.

  • Biodesix, Inc.

  • Laurus Laboratories

For more information about this report visit https://www.researchandmarkets.com/r/kffwgd

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220425005562/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900